Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Sep 25 - Sep 30
Marketed under the brand names Mounjaro (for diabetes) and Zepbound (for weight management in adults with BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity), tirzepatide represents the first dual incretin receptor agonist available in clinical practice
Yi SS, Hwang IK, Shin JH, Choi JH, Lee CH, Kim IY, et al
Seven to twelve months post-treatment, 11 of 12 in the BPC157only group (~92%) and 3 of 4 in the combination group (~75%) reported significant pain relief
External resources NEJM Phase 2 Trial: Triple Hormone Receptor Agonist Retatrutide for Obesity PMC Review: Retatrutide - A Game Changer in Obesity Pharmacotherapy ClinicalTrials.gov: Retatrutide TRIUMPH Clinical Trial Registry Nature Medicine: Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease For researchers serious about optimizing their retatrutide protocols, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, personalized protocol builders, dosing calculators, and a community of thousands who have navigated these exact questions
US$ 27.75
US$ 26.69
US$ 28.23
US$ 29.65
US$ 20.50
